TScan Therapeutics Presents Initial Phase 1 Clinical Results on TSC-100 and TSC-101 at the 65th American Society of Hematology Annual Meeting and Exposition

December 10, 2023

https://www.globenewswire.com/news-release/2023/12/09/2793434/0/en/TScan-Therapeutics-Presents-Initial-Phase-1-Clinical-Results-on-TSC-100-and-TSC-101-at-the-65th-American-Society-of-Hematology-Annual-Meeting-and-Exposition.html

No relapses have occurred in six of six treatment-arm patients, four with follow-up past six months; one of four control-arm patients relapsed at six months and two others required clinical intervention

Read more at globenewswire.com

Related news for (TCRX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.